BIOTRONIK Home Monitoring®

Maximum Reliability Due to Unique Monitoring Technology

Home Monitoring device
T device with RF antenna

- Automatic data transmission
- Daily data transmission, including event IEGMs
- Improved diagnostics with up to 4 IEGMs in daily data transmission[1]
- Notification of transmission gaps
- Minimum energy consumption of the daily data transmission[2]

Mobile transmitter
CardioMessenger Smart

- Easy initialization thanks to plug & play set-up
- Automatic pairing of implanted device and CardioMessenger
- Worldwide data transmission via mobile phone network
- Full patient mobility with battery life of up to 48 h[3]

Online platform
Home Monitoring Service Center



- Automatic data transfer in case of implanted device replacement
- Configuration of monitoring parameters directly on the BIOTRONIK Home Monitoring platform
- Patient-specific event reports
- Event prioritization through intelligent traffic light system

Industry-leading transmission reliability with BIOTRONIK Home Monitoring[4,5]



BIOTRONIK
excellence for life

BIOTRONIK Home Monitoring

Efficient Remote Follow-Up with BIOTRONIK Home Monitoring

BIOTRONIK Home Monitoring can safely replace in-office follow-ups. Patient-oriented remote follow-up spares unnecessary visits to the doctor and improves patient adherence.[2]

Scheduled follow-up | Reception of follow-up data | Data forwarding via mobile phone network | Automatic data analysis and notification of the doctor | Evaluation of follow-up data

SAFE FOLLOW-UP REDUCTION
FDA & CE approved*

Reliable Early Detection with BIOTRONIK Home Monitoring

Continuous monitoring allows early detection of technically and clinically relevant events and prompt intervention.[2]

- Reduction of all-cause mortality risk in heart failure patients[6]
- Fewer patients with worsening heart failure status[6]
- Reduction of inadequate shocks[7]
- Fewer hospitalizations due to atrial fibrillation, strokes and inadequate shock deliveries[7,8]

Detected event | Reception of event data | Data forwarding via mobile phone network | Automatic data analysis and notification of the doctor | Event evaluation

EARLY DETECTION
FDA & CE approved*

MORTALITY REDUCTION
CE approved*

1 As of Inlexa/Intica. **2** Varme N et al.; The TRUST trial. Circulation 2010; 122:325-332; doi: 10.1161/CIRCULATIOPNAHA.110.937409. **3** CardioMessenger Smart. **4** Varma N et al.; Europace Journal 2011; 13(3): Abstract P1026. **5** Crossley G H et al.; The Connect trial. Journal of the American College of Cardiology 2011; 54 (10): 1181-1189. **6** Hindricks G et al.; IN-TIME study. The Lancet 2014: 384(9943). **7** Guedón-Moreau L et al.; ECOST study European Heart Journal 2012. doi: 10.1161/CIRCEP.110.951962. **8** Mabo P et al.; The COMPAS trial. European Heart Journal 2011, doi: 10.1093/eurheartj/ehr419.

BIOTRONIK SE & Co. KG
Woermannkehre 1
12359 Berlin / Germany
www.biotronik.com

BIOTRONIK
excellence for life

433 597/C1911